Albendazole as an alternative therapeutic agent for childhood giardiasis in Turkey.

Abstract

The efficacy of albendazole for the treatment of giardiasis has been indicated by previous in-vitro and in-vivo studies. In order to compare the therapeutic efficacy of albendazole and metronidazole, 107 Giardia-positive children (aged 3-15 years), diagnosed by three consecutive positive stool examinations, were enrolled in the study. Of these children, 52 were given a single daily dose of albendazole 10 mg/kg for 5 days, and 55 were given metronidazole 20 mg/kg daily in three doses for 7 days. Parasite eradication was achieved in 47 (90.4%) of 52 children treated with albendazole and 49 (89.1%) of 55 children treated with metronidazole (p > 0.05). These results suggest that albendazole is an effective treatment option for childhood giardiasis.

• Authors: K Yereli, I C Balcioğlu, P Ertan, E Limoncu, A Onağ
• Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (Clin Microbiol Infect) Vol. 10 Issue 6 Pg. 527-9 (Jun 2004) ISSN: 1198-743X [Print] England
• PMID: 15191380 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Antiprotozoal Agents
• Metronidazole
• Albendazole

Topics

• Adolescent
• Albendazole (administration & dosage, therapeutic use)
• Animals
• Antiprotozoal Agents (administration & dosage, therapeutic use)
• Child
• Child, Preschool
• Female
• Giardia lamblia (drug effects)
• Giardiasis (drug therapy, parasitology)
• Humans
• Male
• Metronidazole (administration & dosage, therapeutic use)
• Treatment Outcome
• Turkey